OrsoBio Reports the First Patient Dosing of TLC-3595 in P-IIa Clinical Trial for the Treatment of Type 2 Diabetes
Shots:
- The first patient has been dosed in a P-IIa clinical trial evaluating the safety, tolerability, and efficacy of two doses of TLC-3595 (selective inhibitor of acetyl-CoA carboxylase 2) in 50 overweight or obese patients with insulin resistance incl. T2D treated with glucose-lowering therapies
- The 1EPs of the trial are improvement in insulin sensitivity based on results from OGTT after 4wks. of therapy while additional exploratory EPs incl. biomarker of glycemic control, fatty acid oxidation, lipids, and MRI/MRS-based assessments of muscle and liver fat
- OrsoBio obtained an exclusive global right in 2022 to an ACC2 inhibitor program with lead compound TLC-3595 from Shionogi & Co., Ltd
Ref: Businesswire | Image: OrsoBio
Related News:- Eli Lilly Reports the US FDA’s Acceptance of sNDA for Jardiance to Treat Type 2 Diabetes
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
